Generic competition · all medicines · read 12 November 2026

Is there a generic of Ruxolitinib Phosphate, and who makes it?

Ruxolitinib Phosphate appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 3 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.

Ruxolitinib Phosphate3 dosage-form groups in the Orange Book

0generic makers listed

Ruxolitinib Phosphate appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
3 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Extended Release, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Jakafi Xr. No generic is listed as marketed.

generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

22 September 2028Exclusivity ODE* Jakafi Xr
22 March 2029Exclusivity PED Jakafi Xr
12 December 2026Patent 9814722
12 December 2026Patent 9206187
12 December 2026Patent 9079912
12 December 2026Patent 11744832
12 December 2026Patent 8530485 drug product
24 December 2027Patent 7598257 drug substance
24 December 2027Patent 8415362 drug substance
12 June 2028Patent 8829013

21 more patents are listed.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Jakafi. No generic is listed as marketed.

generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

24 November 2026Exclusivity PED Jakafi
22 September 2028Exclusivity ODE-373 Jakafi
22 March 2029Exclusivity PED Jakafi
12 December 2026Patent 9079912
12 December 2026Patent 9814722
12 June 2027Patent 9079912*PED
12 June 2027Patent 9814722*PED
24 December 2027Patent 7598257 drug substance
24 December 2027Patent 8415362 drug substance
12 June 2028Patent 8822481
12 June 2028Patent 8829013

8 more patents are listed.

Cream, Topical

Brand listed, no generic listed as marketed

Brand listed as marketed: Opzelura. No generic is listed as marketed.

generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

18 September 2028Exclusivity NPP Opzelura
12 December 2026Patent 9079912
12 December 2026Patent 9974790
12 December 2026Patent 10639310
12 June 2027Patent 9079912*PED
12 June 2027Patent 9974790*PED
12 June 2027Patent 10639310*PED
24 December 2027Patent 7598257 drug substance
24 December 2027Patent 8415362 drug substance

25 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.